Abstract 1490P
Background
Prostate cancer patients, and their clinicians, can benefit from deeper analysis of possible factors of emotional wellbeing.
Methods
Patients completed depression and anxiety questionnaires on the CareAcross personalised support platform. Responses were analysed across several aspects of their diagnosis, treatments and side-effects.
Results
333 prostate cancer patients completed PHQ9 & GAD7 questionnaires, evaluating depression and anxiety, respectively. Regarding depression, the mean score was 7.23 out of 27. For the intervals 0-4, 5-9, 10-14, 15-19, 20-27, patient distribution was 44%, 25%, 15%, 10% and 5%, respectively. As for anxiety, the mean score was 6.58 out of 21. For the intervals 0-4, 5-9, 10-14, 15-21, patient distribution was 44%, 28%, 15% and 13%, respectively. The difference between mean scores was further analysed across segments (detailed in the table). Among the 333 patients, the 113 (34%) diagnosed with metastatic disease experienced higher impact compared to early stage patients (+15% depression and +11% anxiety scores). Of 220 early stage patients, 63 (29%) had been receiving medical treatment; their scores were 8% higher for depression, but 23% lower for anxiety, compared to those who had not. Among patients receiving medical treatment, those with metastatic disease reported similar depression but 28% higher anxiety scores compared to early disease patients. Patients with PSA at diagnosis > 20 reported higher scores (+22% depression; +10% anxiety). Finally, sleep problems and fatigue were correlated with 52-61% higher scores. Table: 1490P
| Stage: | Early (Ν=220) | Metastatic (Ν=113) | Δ |
| Depression | 6.89 | 7.90 | +15% |
| Anxiety | 6.34 | 7.04 | +11% |
| Non-metastatic, and: | No medical treatment (Ν=157) | Medical treatment (Ν=63) | Δ |
| Depression | 6.74 | 7.25 | +8% |
| Anxiety | 6.78 | 5.24 | -23% |
| Medical treatment, and: | Non-metastatic (Ν=63) | Metastatic (Ν=87) | Δ |
| Depression | 7.25 | 7.21 | -1% |
| Anxiety | 5.24 | 6.69 | +28% |
| PSA at diagnosis: | PSA<=20 (Ν=203) | PSA>20 (Ν=102) | Δ |
| Depression | 6.53 | 7.96 | +22% |
| Anxiety | 6.22 | 6.86 | +10% |
| Sleep problems: | Never reported (Ν=116) | Reported (Ν=76) | Δ |
| Depression | 5.18 | 8.18 | +58% |
| Anxiety | 4.61 | 7.34 | +59% |
| Fatigue: | Never reported (Ν=85) | Reported (Ν=109) | Δ |
| Depression | 3.75 | 8.35 | +61% |
| Anxiety | 4.00 | 7.00 | +52% |
Conclusions
The majority of prostate cancer patients reported at least mild anxiety and mild depression. In this analysis of real-world evidence, cancer stage, PSA at diagnosis, treatments, and side-effects, were among the factors affecting patients in several ways. The multiple determinants of emotional wellbeing of prostate cancer patients warrant more research and offer the opportunity for personalised interventions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Care Across Ltd.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.